Literature DB >> 15610167

Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A.

Haibei Hu1, Elizabeth A McCaw, Andrea L O Hebb, Geraldine T Gomez, Eileen M Denovan-Wright.   

Abstract

Huntington's disease (HD) is caused by the inheritance of a copy of the gene encoding mutant huntingtin with an expanded CAG repeat. Phosphodiesterase 10A (PDE10A) mRNA decreases in transgenic HD mice expressing exon 1 of the human huntingtin gene (HD). The mouse PDE10A mRNA is expressed through alternative splicing and polyadenylation in a tissue-specific manner and that transcription of striatal PDE10A mRNA is driven by two promoters. PDE10A2 is the predominant isoform of the gene is expressed in the striatum. Using in situ hybridization and quantitative RT-PCR, we determined that decreased steady-state levels of PDE10A2 mRNA were caused by an altered transcription initiation rate rather than by post-transcriptional mRNA instability in HD mice. Transcription from three initiation sites located within a 50-bp region in the PDE10A2-specific promoter was differentially affected by the presence of the mutant huntingtin transgene. The mouse and human PDE10A2 promoters are highly conserved with respect to the relative position of cis-regulatory elements. Several transcription factors that have been shown to interact with mutant huntingtin, including Sp1, neuron restrictive silencing factor, TATA-binding protein and cAMP-response element binding protein, are unlikely to be involved in mutant huntingtin-induced PDE10A2 transcriptional dysregulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15610167     DOI: 10.1111/j.1460-9568.2004.03796.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  25 in total

1.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

3.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 4.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

5.  Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.

Authors:  Robert B Laprairie; Geraldine T Petr; Yan Sun; Kathryn D Fischer; Eileen M Denovan-Wright; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2018-04-27       Impact factor: 3.921

6.  Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain.

Authors:  Zhude Tu; Jinda Fan; Shihong Li; Lynne A Jones; Jinquan Cui; Prashanth K Padakanti; Jinbin Xu; Dexing Zeng; Kooresh I Shoghi; Joel S Perlmutter; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2011-01-22       Impact factor: 3.641

7.  Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.

Authors:  Joel D Federspiel; Todd M Greco; Krystal K Lum; Ileana M Cristea
Journal:  Mol Cell Proteomics       Date:  2019-04-30       Impact factor: 5.911

8.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

Review 9.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

Review 10.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.